Related Experiment Video
Updated: Aug 23, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Cardiogenic shock
1Sections of Cardiology and Critical Care Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA. shollenb@rush.edu
Insights
Early cardiac catheterization and revascularization improve survival for patients with cardiogenic shock. This strategy, supported by the SHOCK trial, is now standard care for this high-mortality condition.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- High mortality rates persist in cardiogenic shock patients.
- Pathophysiology involves a cycle of ischemia and myocardial dysfunction.
- Viable but nonfunctional myocardium can exacerbate shock.
Purpose of the Study:
- To evaluate the efficacy of emergent cardiac catheterization and revascularization in cardiogenic shock.
- To establish optimal treatment strategies for improving survival rates.
Main Methods:
- The study utilized data from the SHOCK (Should We Intervene Following Myocardial Infarction) multicenter randomized trial.
- Investigated a strategy of rapid diagnosis, supportive therapy, and prompt coronary revascularization.
Main Results:
- Emergent cardiac catheterization and revascularization (angioplasty or surgery) significantly improve survival.
- This strategy is supported by new data from the SHOCK trial.
- For facilities lacking angioplasty, IABP and thrombolysis followed by transfer is a viable option.
Conclusions:
- Emergent cardiac catheterization and revascularization represent the current standard of care for cardiogenic shock.
- Prompt intervention is crucial for improving outcomes in these critically ill patients.
Abstract:
Mortality rates in patients with cardiogenic shock remain frustratingly high. Its pathophysiology involves a downward spiral in which ischemia causes myocardial dysfunction, which in turn worsens ischemia. Areas of viable but nonfunctional myocardium can contribute to the development of cardiogenic shock. Rapid diagnosis and prompt initiation of supportive therapy to maintain blood pressure and cardiac output, followed by expeditious coronary revascularization, are crucial. The SHOCK multicenter randomized trial has provided important new data that support a strategy of emergent cardiac catheterization and revascularization with angioplasty or coronary surgery when feasible. This strategy can improve survival and represents standard therapy at this time. In hospitals without direct angioplasty capability, stabilization with IABP and thrombolysis followed by transfer to a tertiary care facility may be the best option.
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Introduction Cardiac Emergencies
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy

